ClinicalTrials.gg
TerminatedNCT01113970Updated Oct 2, 2026

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

A Phase 1 interventional study of Indibulin in Metastatic Breast Cancer, sponsored by Alaunos Therapeutics. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Alaunos Therapeutics · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor business decision: enrollment closed after the Phase 1 dose escalation, before an MTD was reached. The Phase 2 portion was not conducted.
Updated Oct 2, 2026Now TerminatedNow Completed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a Phase I/II trial of a novel Indibulin dosing schedule for the treatment of metastatic breast cancer. Eligible patients will have measurable or non-measurable, metastatic or unresectable, locally advanced breast cancer and may have received any number of prior therapies for their disease.

It is expected that the Phase I portion will enroll up to 20 patients and the Phase II portion will enroll up to 45 patients.

02

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • Indibulin
  • unresectable, locally advanced breast cancer
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 35 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Alaunos Therapeutics is the lead sponsor of 37 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic confirmation of invasive carcinoma of the breast.
  • Clinical evidence of disease or locally advanced disease not amenable to curative therapy.
  • Measurable or non- according to the Version 1.1 2009.
  • Any number of prior endocrine, biologic or chemotherapy regimens is permitted. All previous chemotherapy and biologic therapy must have been discontinued at least 3 weeks prior to beginning study drug. Endocrine therapy may not be used concurrently with protocol treatment. All acute toxic effects (excluding alopecia or neuropathy) of any prior therapy must have resolved to NCI CTC (version 4.0) Grade ≤ 1 or to baseline
  • Prior radiation therapy is permitted.
  • performance status of 0, 1 or 2.
  • Age ≥ 18 years
  • ≥ 12 weeks
  • Patients with -positive (IHC 3+ or FISH-amplified) breast cancer must have received trastuzumab or have a contradiction to receiving HER2- targeted therapy (such as abnormal )as determined by the treating physician.
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements:

    • Creatinine ≤ 1.5x (ULN)
    • Total ≤ 1.5x ULN
    • or AST ≤ 2.5x ULN
    • ≥ 1.5 x10(9)/L
    • ≥ 100 x10(9)/L
    • ≥ 9g/dL
  • Subjects of must agree to use a barrier method of throughout the study and for 3 months after study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women may not participate.
  • Serious, uncontrolled, concurrent infection.
  • Patients with symptomatic that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic, previously irradiated, stable brain metastases for at least 3 months are not grounds for trial exclusion.
  • Presence of uncontrolled gastrointestinal malabsorption syndrome.
  • Any chemotherapy, radiotherapy or breast cancer directed biologic therapy during the study or within 3 weeks of study start. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry. No is required for hormonal therapies.
  • Concurrent radiation therapy is not permitted during treatment on protocol.
  • History of an invasive second primary diagnosed within the previous 3 years, except for Stage I endometrial or cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
  • Any medical, psychological or social condition that may interfere with the subject's ability to safely participate in the study.
  • Unwillingness to give written or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Single Arm

    open label, single arm, unblinded

    Drug: Indibulin

Interventions

  • Indibulin given orally once a day for 5 days followed by a 9 day rest

    Also known as: ZIO-301, Zybulin(TM)

06

What researchers measure

Primary outcomes

  1. Phase I- Maximum Tolerated Dose

    The primary objective of the Phase I portion of the trial is to determine the maximum tolerated dose (MTD) of Indibulin when given for 5 days followed by a 9 day rest (5-9) using a standard 3+3 dose escalation scheme for the treatment of metastatic breast cancer

    Time frame: Throughout Cycle 1 (28 days)

  2. Phase II- Progression Free Survival

    The primary objective of the Phase II portion of this trial is to examine the efficacy of indibulin for the treatment of metastatic breast cancer at the MTD established in Phase I. The primary endpoint is the proportion of patients who are progression free at 4 months when treated with Indibulin (5-9)at the MTD determined by the phase I portion of the trial.

    Time frame: 4 months

Secondary outcomes

  1. Phase I- Number of participants with Adverse Events as a measure of safety and tolerability

    To evaluate the safety of Indibulin when administered for 5 days followed by a 9 day rest (5-9) in patients with metastatic breast cancer

    Time frame: Duration of study, approximately one year

  2. Phase I- Toxicity

    To describe the Cycle I and overall toxicity rates of indibulin (5-9) using the NCI CTC version 3.

    Time frame: Cycle 1 (28 days), and duration of study (approximately one year)

  3. Phase I- Pharmacokinetics of indibulin in study subject plasma assessed in Cycle 1 Day 1 and Cycle 1 Day 5 per schedule below in Description section.

    To evaluate pharmacokinetics (PK) of Indibulin (5-9) as it is assessed in Cycle 1 Day 1, Day 2, Day 5 and Day 8. Cycle 1 PK schedule as follows: Day 1 immediately pre dose, 1 hour, 2 hours, 4 hours, 6 hours and approximately 24 hours after start of infusion (Cycle 2 Day 1), Day 5 pre-dose and at anytime during Day 8.

    Time frame: During Cycle 1 (28 days)

  4. Phase II- Overall Response Rate

    To estimate the overall response rate (complete response and partial response)associated with Indibulin (5-9) schedule at eth MTD determined by the Phase I portion of this trial in patients with metastatic breast cancer.

    Time frame: At the end of Cycles 4 and 6 (approximately 4 months and 6 months respectively)

  5. Phase II- Rate of Stable Disease

    To estimate the rate of stable disease greater than 6 months associated with the Indibulin (5-9) schedule at the MTD determined by the the Phase I portion of this trial in patients with metastatic breast cancer.

    Time frame: Phase II- greater than 6 months

  6. Phase II- Number of patients with Adverse Events as a measure of safety and tolerability

    To evaluate the safety of Indibulin when administered for 5 days followed by a 9 day rest (5-9) at the MTD determined by the Phase I portion of this trial in patients with metastatic breast cancer.

    Time frame: Throughout study, approximately one year

07

Study locations

4 sites
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
  • Evergreen Hematology Oncology
    Spokane, Washington 99218, United States
  • Northwest Cancer Specialists
    Vancouver, Washington 98684, United States
08

References and documents

Publications

  • Kapoor S, Srivastava S, Panda D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. doi: 10.1038/s41598-018-30376-y. PubMed 30120268 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2010 to primary completion in Sep 2012, 28 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Mar 2010 → Apr 2010 and primary completion May 2013 → Sep 2012.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2010
First posted
Apr 30, 2010
StartActual
Apr 6, 2010was Mar 2010
Primary completionActual
Sep 3, 2012was May 2013
CompletionActual
May 21, 2013
Results delay requested
Sep 28, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed→Terminated Sponsor business decision: enrollment closed after the Phase 1 dose escalation, before an MTD was reached. The Phase 2 portion was not conducted.
changed Sep 29, 2026 · changed Oct 2, 2026
Start date
Mar 2010→Apr 6, 2010 (actual)
Oct 2, 2026
Primary completion
May 1, 2013→Sep 3, 2012
Oct 2, 2026
Study completion
May 2013→May 21, 2013
moved 2 times, Sep 29, 2026 – Oct 2, 2026
Enrollment
60 (estimated)→35 (actual)
Oct 2, 2026
Design
Removed Phase 2
Oct 2, 2026
Show all 2 updates
  1. Oct 2, 2026
    Completed→Terminated
    Why stopped Sponsor business decision: enrollment closed after the Phase 1 dose escalation, before an MTD was reached. The Phase 2 portion was not conducted.
    Start date Mar 2010→Apr 6, 2010 (now actual)
    Primary completion May 1, 2013→Sep 3, 2012
    Study completion Jun 1, 2014→May 21, 2013
    Enrollment 60 (estimated)→35 (actual)
    Design Removed Phase 2
  2. Sep 29, 2026
    Status unknown→Completed
    Study completion May 2013→Jun 1, 2014 (now actual)
    + 3 other changes: index terms, verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01113970
Responsible party
Sponsor
First posted
Apr 30, 2010
Start date
Apr 6, 2010
Primary completion
Sep 3, 2012
Completion
May 21, 2013
Last update
Oct 2, 2026

Study contacts

Jonathan J. Lewis, MD, PhD
study director · ZIOPHARM, Oncology, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indibulin

Start the discussion